Werewolf Therapeutics Inc (HOWL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Werewolf Therapeutics Inc (HOWL) has a cash flow conversion efficiency ratio of -0.868x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.60 Million) by net assets ($12.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Werewolf Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Werewolf Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Werewolf Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Werewolf Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Werewolf Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Karyon Industries Bhd
KLSE:0054
|
0.064x |
|
Signaux Girod
PA:ALGIR
|
0.110x |
|
Orpheus Uranium Ltd
AU:ORP
|
-0.119x |
|
Natural Health Trends Corp
F:NAH
|
-0.048x |
|
Hotel Shilla Co Ltd
KO:008775
|
-0.137x |
|
Kiriacoulis Mediterranean Cruises Shipping S.A.
AT:KYRI
|
N/A |
|
Trinity Watthana Public Company Limited
BK:TNITY
|
0.056x |
|
Ateliers Mecaniques D’Indonesie Tbk PT
JK:AMIN
|
0.114x |
Annual Cash Flow Conversion Efficiency for Werewolf Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Werewolf Therapeutics Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see HOWL company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $24.80 Million | $-60.29 Million | -2.431x | -217.48% |
| 2024-12-31 | $73.39 Million | $-56.19 Million | -0.766x | -161.46% |
| 2023-12-31 | $111.37 Million | $-32.61 Million | -0.293x | +11.76% |
| 2022-12-31 | $122.34 Million | $-40.60 Million | -0.332x | -18.25% |
| 2021-12-31 | $152.79 Million | $-42.88 Million | -0.281x | -34.43% |
| 2020-12-31 | $89.22 Million | $-18.62 Million | -0.209x | +78.63% |
| 2019-12-31 | $9.77 Million | $-9.54 Million | -0.977x | -- |
About Werewolf Therapeutics Inc
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies throu… Read more